Genprex Management

Management Kriterienprüfungen 3/4

Genprex CEO ist Ryan Confer , ernannt in Sep 2016, hat eine Amtszeit von 9.67 Jahren. Die jährliche Gesamtvergütung beträgt $728.87K , bestehend aus 65.9% Gehalt und 34.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.13% der Aktien des Unternehmens, im Wert von $10.90K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.5 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

Ryan Confer

Geschäftsführender

US$728.9k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	65.86%
Amtszeit als Geschäftsführer	9.7yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	4.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.8yrs

Jüngste Management Updates

Recent updates

Analyseartikel • Aug 16

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Genprex (NASDAQ:GNPX) stock rose ~13% on Aug. 15 after the company said that the Safety Review Committee (SRC) approved continuation of a phase 1/2 trial of Reqorsa in combination with AstraZeneca's Tagrisso (osimertinib) to treat patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. The SRC decision followed a review of the first group of patients in the phase 1 portion of the phase 1/2 study called Acclaim-1. "The SRC approval to advance Acclaim-1 to the higher dose in the second cohort of patients is an important milestone that further supports REQORSA's safety profile and brings us one step closer to bringing this potentially ground-breaking gene therapy approach to treating NSCLC to the patients who need it most," said Genprex Chief Medical Officer Mark Berger. The trial includes up to three sequential dose escalation groups, the company said in an Aug. 15 press release.

Analyseartikel • Jun 14

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyseartikel • Feb 09

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Nov 19

Genprex: Limited Clinical Data To Justify Risk

GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes. REQORSA—the company's main pipeline molecule—is targeting the Non-Small-Cell Lung Cancer Market. GNPX's share price is currently trading at around $2 after a quick fall from grace (from $15/share) following its IPO in early 2018. Although a low share price may be an attractive entry point, I believe the company has not yet produced any reliable proof of the clinical efficacy of its therapy. In this article, I will argue a neutral position on GNPX discussing the company's technology, market, and clinical data, to present a balanced view on both risk and opportunity.

Analyseartikel • Oct 27

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Jun 11

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ryan Confer im Vergleich zu den Einnahmen von Genprex verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2026	n/a	n/a	-US$17m
Dec 31 2025	US$729k	US$480k	-US$16m
Sep 30 2025	n/a	n/a	-US$17m
Jun 30 2025	n/a	n/a	-US$18m
Mar 31 2025	n/a	n/a	-US$19m
Dec 31 2024	US$542k	US$462k	-US$21m
Sep 30 2024	n/a	n/a	-US$23m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$28m
Dec 31 2023	US$887k	US$426k	-US$31m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$1m	US$393k	-US$24m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$1m	US$345k	-US$21m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$1m	US$351k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$1m	US$300k	-US$11m

Vergütung im Vergleich zum Markt: RyanDie Gesamtvergütung ($USD728.87K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD647.34K).

Entschädigung vs. Einkommen: RyanDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Ryan Confer (43 yo)

9.7yrs

Amtszeit

US$728,871

Vergütung

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer served a...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ryan Confer	President	9.7yrs	US$728.87k	0.13% $ 10.9k
Mark Berger	Chief Medical Officer	4.7yrs	US$688.60k	0.071% $ 5.9k
David Schloss	Senior Vice President of Human Resources	4.3yrs	keine Daten	keine Daten
Thomas Gallagher	Senior Vice President of Intellectual Property & Licensing	5.7yrs	keine Daten	keine Daten
Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	2.8yrs	keine Daten	keine Daten
Celina Laney	Chief of Staff	no data	keine Daten	keine Daten
Greg Jancarik	Senior Director & Corporate Controller	less than a year	keine Daten	keine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: GNPXDas Führungsteam des Unternehmens gilt als erfahren (4.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ryan Confer	President	2yrs	US$728.87k	0.13% $ 10.9k
Brent Longnecker	Independent Director	6.2yrs	US$88.09k	0.0015% $ 124.0
James E. Rothman	Strategic Advisor to the Board of Directors	13.8yrs	keine Daten	keine Daten
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	keine Daten	keine Daten
Pasi Antero Janne	Member of Scientific & Medical Advisory Board	no data	keine Daten	keine Daten
George Peoples	Member of Clinical Advisory Board	5.3yrs	keine Daten	keine Daten
Shu Kam Mok	Member of Scientific & Medical Advisory Board	no data	keine Daten	keine Daten
George Simon	Member of Scientific & Medical Advisory Board	no data	keine Daten	keine Daten
William Wilson	Independent Director	6.2yrs	US$78.09k	0.0015% $ 124.0
Jose Antonio Toscano	Independent Non-Executive Chairman	6.2yrs	US$103.09k	0.0015% $ 124.0
George Gittes	Member of Scientific Advisory Board	5.5yrs	keine Daten	keine Daten
Michael Morse	Member of Clinical Advisory Board	5.3yrs	keine Daten	keine Daten

5.8yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: GNPXDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/20 00:23
Aktienkurs zum Tagesende	2026/05/20 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Genprex, Inc. wird von 1 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
James Molloy	Alliance Global Partners

Genprex Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Genprex, Inc., Annual General Meeting, Aug 15, 2025

Genprex, Inc Announces Executive Changes

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

High number of new and inexperienced directors

Recent updates

Genprex Inc. Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes

Genprex Inc Receives Patent Grant from the Israel Patent Office for Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Inc Announces Positive Clinical Data on Reqorsa Gene Therapy At Asco Annual Meeting

Genprex, Inc. Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer

New major risk - Financial position

Genprex, Inc. to Present Positive Preclinical Data on Reqorsa Gene Therapy for Lung Cancer At the 2026 AACR Annual Meeting

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex, Inc. Announces Ip Australia's Intent to Grant Patent for Reqorsa®? Gene Therapy in Combination with Pd-L1 Antibodies to Treat Cancers

Genprex, Inc. Provides Clinical Update on Diabetes Gene Therapy Program

Genprex Regains Compliance with the Bid Price Requirement and Receives Extension to Regain Compliance with Nasdaq Stockholders Equity Requirement

Genprex, Inc. Announces the Publication of Data from Its Acclaim-1 Phase 1 Clinical Trial of Reqorsa®? Gene Therapy in Combination with Tagrisso®? (Osimertinib) in Patients with Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex, Inc. has filed a Follow-on Equity Offering in the amount of $3.40002 million.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer At the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex, Inc. has filed a Follow-on Equity Offering in the amount of $2.731003 million.

Genprex Inc Receives Exception to Regain Compliance with Nasdaq Listing Requirements

New major risk - Share price stability

Genprex, Inc. Receives Non-Compliance Letter from Listing Qualifications Staff of the Nasdaq Stock Market

Genprex, Inc. Receives Notice of Allowance for Multiple Patents for Reqorsa®? Gene Therapy with Pd-L1 and Pd-1 Antibodies to Treat Cancers

Genprex, Inc. has withdrawn its Follow-on Equity Offering.

Genprex, Inc., Annual General Meeting, Aug 15, 2025

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy At the 2025 American Diabetes Association 85Th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System

Genprex Confirms Regains Compliance with Nasdaq Listing Requirements

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa®? Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer At the 2025 Aacr Annual Meeting

Genprex Selects to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa®? Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex, Inc. announced delayed annual 10-K filing

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System Is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Genprex, Inc. Announces First Patient Has Been Enrolled and Dosed in the Phase 2 Expansion Portion of the Company’S Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

New major risk - Shareholder dilution

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Price target increased to US$6.23

High number of new and inexperienced directors

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans